Health
Neutrolis announces development of first-in-class therapy to target NETs in COVID-19 patients – News-Medical.Net
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemica…
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.
We believe NETs are the common factor that explains the …
-
Business15 hours ago10 ASX shares to buy after the market selloff
-
General18 hours ago‘We are here for you’: PM to bring help to flood zones
-
General17 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
General14 hours agoStephanie Scott’s murder caused a ‘seismic’ shock in Leeton, and the hurt remains